Advertisement
A vs RGEN
Which Stock Would AI Choose? Agilent Technologies (A) vs. Repligen Corporation (RGEN) Stock Comparison
Key Takeaways
- Agilent Technologies (A) and Repligen Corporation (RGEN) both operate in the life sciences and biopharma tools sector, with A offering broader analytical instrumentation exposure and RGEN focusing more narrowly on bioprocessing solutions.
- In recent market activity, RGEN has delivered stronger year-to-date performance compared with A, reflecting differences in growth momentum and sector positioning.
- A reported solid first-quarter fiscal 2026 results with revenue growth and raised full-year guidance, supported by demand in clinical and biopharmaceutical markets.
- RGEN posted a first-quarter 2026 earnings beat with double-digit revenue growth, though full-year guidance came in slightly below some analyst expectations.
- Both stocks trade with elevated valuations typical of growth-oriented healthcare equipment names, with A showing more stable long-term returns and RGEN exhibiting higher volatility.
- Relative performance highlights trade-offs between A’s diversified revenue base and RGEN’s higher-beta exposure to biomanufacturing trends.
Introduction
Agilent Technologies (A) and Repligen Corporation (RGEN) represent two distinct yet overlapping plays within the life sciences ecosystem. A provides a wide range of analytical instruments, diagnostics, and services used across research, clinical, and applied markets. RGEN specializes in bioprocessing tools essential for biologic drug manufacturing. This comparison appeals to investors and traders seeking exposure to healthcare innovation, particularly those evaluating relative momentum, valuation, and sector-specific catalysts in the current market environment. The analysis draws on verifiable financial metrics and recent developments to highlight key contrasts.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) develops and commercializes analytical instrumentation, consumables, and services for life sciences, diagnostics, and applied chemical markets. In recent weeks, the stock has shown resilience amid broader market fluctuations, with year-to-date returns outpacing the S&P 500. First-quarter fiscal 2026 results, released in late February, featured revenue of $1.80 billion, up 7% reported and 4.4% on a core basis, alongside non-GAAP EPS growth. Strength in the clinical business and order growth contributed to an upgraded full-year revenue outlook. Upcoming second-quarter results, scheduled for release on May 27, 2026, represent a near-term catalyst. Sentiment has been supported by improving demand signals in biopharmaceutical and diagnostics end markets, though longer-term returns remain more modest than the broader index.
Repligen Corporation (RGEN) Overview and Recent Performance
Repligen Corporation (RGEN) supplies bioprocessing products and systems used in the manufacture of biologic drugs. The company delivered a first-quarter 2026 earnings beat on May 5, with revenue rising 14.8% year-over-year to $194.3 million and EPS exceeding consensus estimates. Full-year 2026 revenue guidance of $803 million to $833 million reflected measured expectations relative to some analyst forecasts. In recent market activity, the stock has posted notably stronger year-to-date gains than the S&P 500, though it has experienced volatility tied to insider activity and sector rotation. Performance reflects ongoing expansion in biomanufacturing demand, tempered by a wider valuation range compared with larger peers.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this focused section. Available bots span diverse trading styles, strategies, timeframes, performance metrics, and ticker universes, enabling users to review statistical profiles before engaging. This resource provides transparent data on historical results and suitability factors. Explore the Trending AI Robots page to review current options and their detailed performance characteristics.
Head-to-Head Comparison
Agilent Technologies (A) operates a diversified business model spanning instruments, diagnostics, and services, providing broader exposure across research and clinical applications. Repligen Corporation (RGEN) maintains a more concentrated focus on bioprocessing, resulting in higher sensitivity to biologic drug production cycles. Recent momentum favors RGEN on a year-to-date basis, while A has delivered more consistent multi-year returns. Risk factors include A’s exposure to capital equipment spending cycles and RGEN’s greater volatility from product concentration and smaller market capitalization. Both companies benefit from biopharma sector tailwinds, yet A’s scale supports steadier cash flows, whereas RGEN offers potentially higher growth leverage in manufacturing demand. Market sentiment reflects these trade-offs, with analysts maintaining generally constructive ratings on both amid elevated valuation multiples.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative year-to-date momentum, and earnings delivery, Tickeron’s AI models would currently assign a higher probabilistic weighting to Repligen Corporation (RGEN) over Agilent Technologies (A). RGEN’s stronger recent performance and earnings beat provide clearer near-term signals, though A’s diversification offers greater stability in varied market conditions. This assessment remains probabilistic and tied to current data patterns rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and RGEN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 0 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while RGEN’s TA Score has 7 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- RGEN’s TA Score: 7 bullish, 3 bearish.
Price Growth
A (@Medical Specialties) experienced а -0.07% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -1.32% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.28%. For the same industry, the average monthly price growth was +13.41%, and the average quarterly price growth was -7.34%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.97%. For the same industry, the average monthly price growth was -0.88%, and the average quarterly price growth was -13.78%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
RGEN is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (-3.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-2.97% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| A | RGEN | A / RGEN | |
| Capitalization | 38.3B | 6.9B | 555% |
| EBITDA | 1.82B | 176M | 1,036% |
| Gain YTD | -0.058 | -25.357 | 0% |
| P/E Ratio | 27.20 | 134.41 | 20% |
| Revenue | 7.07B | 763M | 926% |
| Total Cash | 1.76B | 785M | 224% |
| Total Debt | 3.35B | 688M | 488% |
A | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 46 | 90 | |
PRICE GROWTH RATING 1..100 | 43 | 58 | |
P/E GROWTH RATING 1..100 | 55 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is significantly better than the same rating for RGEN (87). This means that A’s stock grew significantly faster than RGEN’s over the last 12 months.
A's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as RGEN (100). This means that A’s stock grew similarly to RGEN’s over the last 12 months.
A's SMR Rating (46) in the Biotechnology industry is somewhat better than the same rating for RGEN (90). This means that A’s stock grew somewhat faster than RGEN’s over the last 12 months.
A's Price Growth Rating (43) in the Biotechnology industry is in the same range as RGEN (58). This means that A’s stock grew similarly to RGEN’s over the last 12 months.
A's P/E Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for RGEN (100). This means that A’s stock grew somewhat faster than RGEN’s over the last 12 months.
| A | RGEN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 52% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 82% |
| Advances ODDS (%) | 3 days ago 60% | 3 days ago 74% |
| Declines ODDS (%) | 27 days ago 62% | 5 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 63% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 83% |
Advertisement